Displaying drugs 11126 - 11150 of 12842 in total
GYM329
GYM329 is a recombinant humanized IgG1-based monoclonal antibody which binds to human latent myostatin in a pH-dependent manner
Investigational
VCA-894A
VCA-894A is a synthetic 2'-O-methoxyethyl phosphorothioate oligoribonucleotide sodium salt consisting of 19 nucleotide residues with the sequence 5'-MeCMeUGMeUGGAAGMeUGAGGGMeCMeCAG-3'
Investigational
AOC 1001
AOC 1001 is an antibody oligonucleotide conjugate (AOC), comprised of a human transferrin receptor 1 (TfR1) targeting, effector function null, humanized IgG1 antibody (AV01mAb) conjugated to one small interfering RNA (siRNA).
Investigational
ABBV-011
ABBV-011 is an antibody-drug conjugate of humanized, cysteine-engineered IgG1 monoclonal antibody targeting seizure-related 6 homolog conjugated to N-acetyl-gamma-calicheamicin.
Investigational
Prizloncabtagene autoleucel
C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Investigational
VOR33
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.
Investigational
TTX-MC138
TTX-MC138 is an antisense oligonucleotide targeting miR-10b. It is under investigation for the treatment of various metastatic cancers.
Investigational
CYNK-101
CYNK-101 is an allogeneic human placental hematopoietic stem cell-derived natural killer (NK) cell therapy product that is genetically modified to express a variant of CD16 (CD16VP).
Investigational
CLZ-2002
CLZ-2002 consists of allogeneic mesenchymal stem cells derived neuronal regeneration-promoting cells.
Investigational
MT-401
MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.
Investigational
TUM012
TUM012 is a synthetic polymer PEG conjugated to a phospholipid anchor (2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine)
Investigational
MBX-2109
MBX-2109 is a long-acting parathyroid hormone peptide prodrug under investigation for the treatment of hyperparathyroidism.
Investigational
HG004
Investigational
BG1805
BG1805 is an investigational anti-CLL1 chimeric antigen receptor (CAR) T-cell therapy.
Investigational
Autologous adipose-derived stromal vascular fraction cells
Investigational
Recombinant human insulin-like growth factor 1
Investigational
Rovaleucel
Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.
Investigational
Metelimumab
Metelimumab (CAT-192) is a monoclonal antibody targeted against transforming growth factor (TGF) beta-1.
Investigational
TN-201
TN-201 is a gene therapy comprising a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human MYBPC3 gene.
Investigational
RVT-3101
RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15. It is being investigated for ulcerative colitis.
Investigational
Certepetide
Investigational
Dilanubicel
Dilanubicel consists of ex vivo expanded hematopoietic stem and progenitor cells.
Investigational
RCT1100
RCT1100 is an investigational mRNA-based therapeutic that aims to treat primary ciliary dyskinesia caused by pathogenic mutations in DNAI1.
Investigational
Unasnemab
Unasnemab is under investigation in clinical trial NCT04683848 (Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury).
Investigational
Displaying drugs 11126 - 11150 of 12842 in total